The data shown below were collected from the profiles of 31 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
|
|---|---|
| Published in |
Cancer Discovery, February 2021
|
| DOI | 10.1158/2159-8290.cd-20-1465 |
| Pubmed ID | |
| Authors |
Vinod A Pullarkat, Norman J Lacayo, Elias Jabbour, Jeffrey E Rubnitz, Ashish Bajel, Theodore W Laetsch, Jessica Leonard, Susan I Colace, Seong Lin Khaw, Shaun A Fleming, Ryan J Mattison, Robin Norris, Joseph T Opferman, Kathryn G Roberts, Yaqi Zhao, Chunxu Qu, Mohamed Badawi, Michelle Schmidt, Bo Tong, John C Pesko, Yan Sun, Jeremy A Ross, Deeksha Vishwamitra, Lindsey Rosenwinkel, Su Young Kim, Amanda Jacobson, Charles G Mullighan, Thomas B Alexander, Wendy Stock |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 19% |
| Belgium | 1 | 3% |
| Unknown | 24 | 77% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 16 | 52% |
| Scientists | 9 | 29% |
| Practitioners (doctors, other healthcare professionals) | 3 | 10% |
| Science communicators (journalists, bloggers, editors) | 3 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 160 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 160 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 18 | 11% |
| Student > Ph. D. Student | 15 | 9% |
| Student > Bachelor | 9 | 6% |
| Student > Postgraduate | 7 | 4% |
| Student > Master | 7 | 4% |
| Other | 24 | 15% |
| Unknown | 80 | 50% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 36 | 23% |
| Biochemistry, Genetics and Molecular Biology | 18 | 11% |
| Immunology and Microbiology | 7 | 4% |
| Unspecified | 5 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 2% |
| Other | 7 | 4% |
| Unknown | 84 | 53% |
Attention Score in Context
This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 February 2024.
All research outputs
#1,136,758
of 26,523,931 outputs
Outputs from Cancer Discovery
#588
of 4,231 outputs
Outputs of similar age
#31,098
of 461,936 outputs
Outputs of similar age from Cancer Discovery
#49
of 198 outputs
Altmetric has tracked 26,523,931 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,231 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.9. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 461,936 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 198 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.